@ShahidNShah
Digital Health Tools Need a New Benchmark (and Evidence)
The good AI and healthtech can do is undisputed, but testing new technology using old methods is holding it back. Currently, only 20% of healthcare companies producing digital health technologies have the necessary scientific evidence to back up the benefits they claim to provide. In the future, regulators and payers (such as insurance companies and healthcare providers) will require more clarity on the evidence for these technologies, leading to increased scrutiny and a consensus on the ways in which this evidence should be generated.
In the future, clinical simulations and synthetic data (mock data based on real patient data) will become more widely accepted as a way to generate evidence for these technologies, and that programs such as the Early Value Assessment Program for Digital Tools will help clinicians properly evaluate the claims made by digital health companies.
Continue reading at ired.com
Make faster decisions with community advice
- Alembic Pharma gets USFDA nod for generic drug to treat breast cancer
- Healthcare Private Equity in 2022: Challenges and Opportunities for Digital Health Investment
- Patients and physicians see value from telehealth, but nurses and staff see more work
- What Is Value Based Care, And Why Is The Healthcare Industry Suddenly So Interested In It?
- Cybersecurity Roundup 2022: A Year of Ongoing Threats
Next Article
-
Healthcare Private Equity in 2022: Challenges and Opportunities for Digital Health Investment
As we look out over the horizon to 2023, we would anticipate a rebound of investment in the digital health space but with a simultaneous and a continuing level of focused regulatory diligence as this …
Posted Dec 27, 2022 Digital Health Investments Private Equity & Principal Investors